X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
CRN00808 (paltusotine) is an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is being evaluated for the treatment of patients with non-pharmacologically treated acromegaly.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
Crinetics lead product candidate CRN00808 (paltusotine), an SST2 agonist. Currently, it is being evaluated in the Phase II clinical trial studies for the treatment of Carcinoid Syndrome.
Lead Product(s): Paltusotine
Therapeutic Area: Oncology Product Name: CRN00808
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
Crinetics intends to use the net proceeds from the private placement to fund research and development of its clinical-stage product CRN00808 (paltusotine) for the treatment of Acromegaly rare hormonal disorder.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adage Capital Partners
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 28, 2024
Details:
CRN-00808 (paltusotine) is the first oral, once-daily selectively-targeted somatostatin receptor type 2 (SST2) agonist and is currently in investigational Phase 3 studies for acromegaly and a Phase 2 study for carcinoid syndrome.
Lead Product(s): Paltusotine
Therapeutic Area: Oncology Product Name: CRN-00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
The proceeds will fund development of CRN00808 (paltusotine), a small molecule SST2 agonist, in Phase 3 for acromegaly and Phase 2 for carcinoid syndrome and CRN04894, a small molecule ACTH antagonist, in Phase 2 for Cushing’s disease and congenital adrenal hyperplasia.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 12, 2023
Details:
The proceeds will fund development of CRN00808 (paltusotine), a small molecule SST2 agonist, in Phase 3 for acromegaly and Phase 2 for carcinoid syndrome and CRN04894, a small molecule ACTH antagonist, in Phase 2 for Cushing’s disease and congenital adrenal hyperplasia.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 11, 2023
Details:
CRN00808 (paltusotine) is the first oral, once-daily selectively targeted somatostatin receptor type 2 (SST2) agonist and is currently in Phase 3 investigational studies for acromegaly.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2023
Details:
The results show that CRN00808 (paltusotine), an investigational compound, lowered and maintained insulin-like growth factor-1 (IGF-1) at levels comparable to prior injected SRL therapy for up to 103 weeks in participants living with acromegaly.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
CRN00808 (paltusotine) is an investigational, orally available nonpeptide agonist that designed to be selective for somatostatin receptor type 2. It was designed by Crinetics discovery team to provide oral option for patients with acromegaly and neuroendocrine tumors.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2022
Details:
Crinetics intends to use the net proceeds from the offering to fund the development of paltusotine, CRN04777, CRN04894 and its other research and development programs, and for working capital and general corporate purposes.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SVB Leerink
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 18, 2022
Details:
Crinetics intends to use the net proceeds from the proposed offering to fund the development of paltusotine (CRN00808), CRN04777, CRN04894 and its other research and development programs, and for working capital and general corporate purposes.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SVB Leerink
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 12, 2022
Details:
Paltusotine is Crinetics’ investigational, orally available nonpeptide somatostatin receptor type 2 (SST2) agonist being evaluated as a treatment for acromegaly and neuroendocrine tumors (NETs), including NETs complicated by carcinoid syndrome.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanwa Kagaku Kenkyusho
Deal Size: Undisclosed Upfront Cash: $13.0 million
Deal Type: Licensing Agreement February 28, 2022
Details:
A previously completed Phase 1 trial of paltusotine showed clinical proof of concept by providing evidence of potent suppression of the growth hormone axis in healthy volunteers.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2021
Details:
Crinetics intends to use the net proceeds from the proposed offering to fund the development of paltusotine and its other research and development programs, and for working capital and general corporate purposes.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Frazier Healthcare Partners
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 29, 2021
Details:
A presentation on the company’s orally administered, small molecule adrenocorticotropic hormone (ACTH) antagonist was selected for a late-breaking session at the virtual European Congress of Endocrinology (eECE).
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2020
Details:
The orphan drug designation by the FDA for paltusotine to treat acromegaly validates the encouraging clinical data that has been observed so far in the Phase 2 ACROBAT Edge clinical trial.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
28 patients have completed the open-label Edge trial measuring IGF-1 levels after 13 weeks of treatment when patients with acromegaly were switched to once daily oral paltusotine from commercially available depot injections of the peptide somatostatin receptor ligands (SRLs).
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2020
Details:
Crinetics intends to use the net proceeds to fund the development of paltusotine and its other research and development programs, and for working capital and general corporate purposes.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SVB Leerink
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering April 14, 2020
Details:
Data from patients who have completed the ongoing open label Edge trial show that IGF-1 levels were maintained after 13 weeks of treatment when patients were switched to once daily oral paltusotine.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
